These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37608917)

  • 1. Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York City.
    Sunny S; Tran A; Lee J; Abdallah M; Chaudhry N; Quale J
    Open Forum Infect Dis; 2023 Aug; 10(8):ofad426. PubMed ID: 37608917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study.
    Roddy J; Wells D; Schenck K; Santosh S; Santosh S
    Crit Care Explor; 2022 May; 4(5):e0702. PubMed ID: 35783551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib versus tocilizumab in critically ill COVID-19 patients: A retrospective cohort study.
    Conroy GM; Bauer SR; Pallotta AM; Duggal A; Wang L; Sacha GL
    Pharmacotherapy; 2024 Jan; 44(1):28-38. PubMed ID: 37593883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 7. Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.
    Reid NK; Joyner KR; Lewis-Wolfson TD
    Ann Pharmacother; 2023 Jul; 57(7):769-775. PubMed ID: 36314277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study.
    Kojima Y; Nakakubo S; Takei N; Kamada K; Yamashita Y; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    Medicina (Kaunas); 2022 Apr; 58(4):. PubMed ID: 35454352
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone.
    Wong CKH; Lau KTK; Au ICH; Xiong X; Chung MSH; Leung BYC; Lau EHY; Cowling BJ
    Front Pharmacol; 2022; 13():866441. PubMed ID: 35707401
    [No Abstract]   [Full Text] [Related]  

  • 11. Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort.
    Karolyi M; Gruebl A; Omid S; Saak M; Pawelka E; Hoepler W; Kelani H; Kuran A; Laferl H; Ott C; Pereyra D; Santol J; Seitz T; Traugott M; Assinger A; Wenisch C; Zoufaly A
    Infection; 2023 Aug; 51(4):851-858. PubMed ID: 36083403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes among Hospitalized COVID-19 Patients Who Received Baricitinib or Tocilizumab in Addition to Standard of Care.
    Walker CP; Hurlock NP; Deb S
    Diseases; 2024 May; 12(5):. PubMed ID: 38785762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

  • 14. Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19.
    Peterson JH; Paranjape NS; Grundlingh N; Priestley JL
    Crit Care Med; 2023 Mar; 51(3):337-346. PubMed ID: 36729439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis.
    Zhang J; Fan X; Zhang X; Jiang F; Wu Y; Yang B; Li X; Liu D
    Front Pharmacol; 2023; 14():1293331. PubMed ID: 38074144
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib vs tocilizumab treatment for hospitalized adult patients with severe COVID-19 and associated cytokine storm: a prospective, investigational, real-world study.
    Lakatos B; Szabó BG; Bobek I; Kiss-Dala N; Gáspár Z; Riczu A; Petrik B; Farkas BF; Sebestyén G; Gopcsa L; Bekő G; Sinkó J; Reményi P; Szlávik J; Mathiász D; Vályi-Nagy I
    Int J Infect Dis; 2022 Dec; 125():233-240. PubMed ID: 36328291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis.
    Albuquerque AM; Eckert I; Tramujas L; Butler-Laporte G; McDonald EG; Brophy JM; Lee TC
    Clin Microbiol Infect; 2023 Jan; 29(1):13-21. PubMed ID: 35863630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial.
    Dastan F; Jamaati H; Barati S; Varmazyar S; Yousefian S; Niknami E; Tabarsi P
    Front Pharmacol; 2023; 14():1265541. PubMed ID: 37927607
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study.
    Kojima Y; Nakakubo S; Kamada K; Yamashita Y; Takei N; Nakamura J; Matsumoto M; Horii H; Sato K; Shima H; Suzuki M; Konno S
    J Med Virol; 2022 Dec; 94(12):5702-5712. PubMed ID: 35916111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.